Research and Markets: Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023 Report Presents Analysis and Insights

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/kq748x/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market, 2013 - 2023" report to their offering.

The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are:

- Fc Glycoengineering (referred to as Glycoengineering' in the report)

- Fc Protein engineering

The base year for the report is 2012, with estimated sales data presented for the single engineered antibody - Mogamulizumab - marketed so far. One of the primary objectives of this report is to understand the current and future status of the engineered antibody therapeutics market. This is done by analysing:

- Molecules in pipeline and drugs approved for marketing across various markets

- Research programs, focused on engineered antibody therapeutics, of global pharmaceutical companies and recently established start-ups

- Technologies to produce engineered antibodies

- Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs

The report provides short-mid term and long term market forecasts for the periods 2013 - 2018 and 2018 - 2023, respectively. Discussed, in detail, are the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the forecasted sales of

- Seven marketed and pipeline glycoengineered antibodies and

- Three pipeline Fc protein engineered antibodies

Companies Mentioned:

- ABN AMRO Capital

- Amgen

- Astra Zeneca

- Boehringer Ingelheim

- Bristol Myers Squibb

- Deutsche Venture Capital

- Dong-A Pharmaceutical

- Eli Lilly

- Five Prime Therapeutics

- Genentech

- Gilde Investment Management

- GSK

- Hanwha Chemical

- Human Genome Sciences

- ImmunGene

- KaloBios

- Life Science Pharmaceuticals

- MacroGenics

- Nippon Shinyaku

- Novartis Venture Fund

- Ortho-McNeil Janssen Pharmaceutical

- Pfizer

- Quester Capital Management

- Regeneron Pharmaceuticals

- Roche

- Sanofi

- Shanghai CP Guojian

- Teva Pharmaceuticals

- TG Therapeutics

- Vivalis

- Watson Pharmaceuticals

- Xencor

- Zymeworks

For more information visit http://www.researchandmarkets.com/research/kq748x/fc_protein_and

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals